Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19 : a structured summary of a study protocol for a randomised controlled trial

Hanna, Catherine R. and Blyth, Kevin G. and Burley, Glenn and Carmichael, Samantha and Evans, Carol and Hinsley, Samantha and Khadra, Ibrahim and Khoo, Saye and Lewsley, Liz-Anne and Jones, Robert R. and Sharma, Raman and Taladriz-Sender, Andrea and Thomson, Emma C. and Scott, Janet T. (2020) Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19 : a structured summary of a study protocol for a randomised controlled trial. Trials, 21. 935. ISSN 1745-6215

[img]
Preview
Text (Hanna-etal-Trials-2020-Glasgow-early-treatment-arm-favirpiravir-GETAFIX-for-adults-with-early-stage-COVID-19)
Hanna_etal_Trials_2020_Glasgow_early_treatment_arm_favirpiravir_GETAFIX_for_adults_with_early_stage_COVID_19.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (455kB)| Preview

    Abstract

    The GETAFIX trial will test the hypothesis that favipiravir is a more effective treatment for COVID-19 infection in patients who have early stage disease, compared to current standard of care. This study will also provide an important opportunity to investigate the safety and tolerability of favipiravir, the pharmacokinetic and pharmacodynamic profile of this drug and mechanisms of resistance in the context of COVID-19 infection, as well as the effect of favipiravir on hospitalisation duration and the post COVID-19 health and psycho-social wellbeing of patients recruited to the study.